Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells

The JAK/STAT pathway is constitutively activated in myeloproliferative neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor. The JAK2(V617F) mutation leads to constitutive STAT3 phosphorylation and potentially leads to inhibition of Stathmin 1 activity via STAT3. In support of...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado-Neto, João Agostinho, de Melo Campos, Paula, Favaro, Patricia, Lazarini, Mariana, da Silva Santos Duarte, Adriana, Lorand-Metze, Irene, Costa, Fernando Ferreira, Olalla Saad, Sara Teresinha, Traina, Fabiola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745747/
https://www.ncbi.nlm.nih.gov/pubmed/26356819

Ejemplares similares

Ejemplares similares